Randomized Clinical Trial: Effects of β-Hydroxy-β-Methylbutyrate (HMB)-Enriched vs. HMB-Free Oral Nutritional Supplementation in Malnourished Cirrhotic Patients
Authors:
- Silvia EspinaSilvia Espina
- Alejandro Sanz-ParisAlejandro Sanz-Paris
- Yolanda Gonzalez-IrazabalYolanda Gonzalez-Irazabal
- Patricia Pérez-MatutePatricia Pérez-Matute
- Fernando AndradeFernando Andrade
- Beatriz Garcia-RodriguezBeatriz Garcia-Rodriguez
- Christian CarpénéChristian Carpéné
- Alexia ZakaroffAlexia Zakaroff
- Vanesa Bernal-MonterdeVanesa Bernal-Monterde
- Javier Fuentes-OlmoJavier Fuentes-Olmo
- Jose M. Arbones-MainarJose M. Arbones-Mainar
Open Access
Abstract
β-Hydroxy-β-methylbutyrate (HMB) supplementation increases muscle and strength mass in some muscle-wasting disorders. Malnutrition and sarcopenia are often present in liver cirrhosis. We aimed to investigate the effects of oral HMB supplementation on changes in body composition and liver status in patients with cirrhosis and malnutrition. In a randomized, controlled, double-blind trial, 43 individuals were randomized to receive twice a day and for 12 weeks an oral nutritional supplement (ONS) enriched with 1.5 g of calcium HMB per bottle or another supplement with similar composition devoid of HMB. Inclusion criteria were liver cirrhosis with at least one previous decompensation and clinical malnutrition. Liver function, plasma biochemistry analyses, and physical condition assessment were carried out at baseline, then after six and 12 weeks of supplementation. A total of 34 patients completed the clinical trial. An improvement in liver function and an increase in fat mass index were observed in both groups. None of the two ONS changed the fat-free mass. However, we observed an upward trend in handgrip strength and a downward trend in minimal hepatic encephalopathy in the HMB group. At the end of the trial and regardless of the supplement administered, fat mass content increased with no change in fat-free mass, while liver function scores and nutritional analytic markers also improved.Keywords
Funding Information
- Fondo Europeo de Desarrollo Regional (FEDER) via the Trans-Pyrenean cooperation network for biomedical research (Refbio2, PI17/02268, B03_20R)
- Instituto de Salud Carlos III (Refbio2, PI17/02268, B03_20R)
- Regional Government of Aragón (Refbio2, PI17/02268, B03_20R)
- FEDER Aragón 2014–2020: “Construyendo Europa desde Aragón” (Refbio2, PI17/02268, B03_20R)
This publication has 46 references indexed in Scilit:
- Malnutrition in Cirrhosis: Contribution and Consequences of Sarcopenia on Metabolic and Clinical ResponsesClinics in Liver Disease, 2012
- Regulation Mechanisms and Signaling Pathways of AutophagyAnnual Review of Genetics, 2009
- Effect of liver cirrhosis on body composition: Evidence of significant depletion even in mild diseaseJournal of Gastroenterology and Hepatology, 2005
- Analyzing incomplete longitudinal clinical trial dataBiostatistics, 2004
- Analyzing incomplete longitudinal clinical trial dataBiostatistics, 2004
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001
- The assessment of body composition in patients with cirrhosisEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- What is subjective global assessment of nutritional status?Journal of Parenteral and Enteral Nutrition, 1987
- Splanchnic and leg exchange of free fatty acids in patients with liver cirrhosisJournal of Hepatology, 1986
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973